GlassScriptPhysician profile
Katie Wohlgemuth
NPI 1548920820
$1,881.92
in general payments reported to CMS, 2019-2025
19 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $74.52 · 2024: $788 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.65 |
| Education | $155.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $442.08 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Amgen INC. | $264.15 | 2024-2025 | Tezspire, Repatha, Otezla |
| Regeneron Healthcare Solutions, INC. | $235.99 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $181.86 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $155.10 | 2024-2025 | |
| Abbvie INC. | $105.51 | 2023-2024 | |
| Convatec INC. | $104.18 | 2024 | |
| Genzyme Corporation | $61.25 | 2024-2025 | |
| Genentech USA, INC. | $60.17 | 2025 | Xolair |
| Vertex Pharmaceuticals Incorporated | $48.00 | 2025 | |
| Lilly USA, LLC | $39.58 | 2024-2025 | Ebglyss, Jardiance |
| Biocryst US Sales Co., LLC | $37.60 | 2025 | Orladeyo |
| Integra Lifesciences Corporation | $35.20 | 2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Ars Pharmaceuticals Operations, INC. | $33.45 | 2025 | Neffy |
| Cochlear Americas | $19.43 | 2025 | Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15.65 | 2025 | Propel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.58 | 2023 | Jardiance |
| Supernus Pharmaceuticals, INC. | $14.09 | 2024 | Qelbree |
| Idorsia Pharmaceuticals US INC | $14.05 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Wohlgemuth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.